Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

Trial Details

NCT ID
NCT07080216
Phase
PHASE1 / PHASE2
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • ZG005
  • Gecacitinib
  • Bevacizumab
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Fully understand the study and voluntarily sign the informed consent form.
  • Female 18-75 years of age;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →